AMENDMENTS TO THE CLAIMS

1. - 25. (**Canceled**)

26. (**Currently Amended**) A ~~P~~process for preparing ~~the soluble, stable, and concentrated pharmaceutical~~ compositions ~~of ritonavir of claim 1~~ comprising 10% to 50% w/w of ritonavir comprising the following steps:

(a~~2~~) dissolving 10% to 50% w/w of ritonavir in an excess amount of an alcoholic solvent of C_2-C_4, ~~under controlled~~ at a temperature between 30°C and 45°C to make a first mixture;

(b~~2~~) eliminating solid particles from said first mixture by filtration;

(c~~2~~) evaporating the alcoholic solvent from ~~said~~ the filtered first mixture under reduced pressure at ~~low~~ a temperature not higher than 40°C to about half of its initial concentration;

(d~~2~~) adding to ~~said~~ the filtered and concentrated first mixture an alcoholic co-solvent in an amount ranging from 5% to 20% w/w, a medium chain mono/diglycerides mixture in an amount ranging from 20% to 40% w/w, an antioxidant in an amount ranging from 0.001% to 2% w/w, an emulsion-stabilizing agent in an amount up to 60% w/w and a polarity corrector in an amount up to 0.5% w/w to make a second mixture;

(e~~2~~) removing the alcoholic solvent of step (a~~2~~) from said second mixture by distilling under reduced pressure to correct the weight of said second mixture until the remaining quantity of alcoholic solvent is between 5% and 20% w/w of the composition;

(f~~2~~) adding to ~~said~~ the distilled second mixture a surfactant in an amount ranging from 0.1% to 20% w/w under continuous stirring, until ~~said surfactant added to said distilled~~ the second mixture becomes a clear solution, thereby obtaining a soluble, stable and concentrated ritonavir pharmaceutical composition; and

(g~~2~~) correcting the final weight of ~~said~~ the pharmaceutical composition by adding the alcoholic solvent employed in the step (a~~2~~).

27. (**Currently Amended**) The process in accordance with claim 26, wherein the alcoholic solvent used in step (a~~2~~) is ethanol.

28. - 29. (**Canceled**)

30. (**Currently Amended**) The process in accordance with claim 26, wherein the co-solvent employed in step (d~~2~~) is propylene glycol.

31. (**Canceled**)

32. (**Currently Amended**) The process in accordance with claim 26, wherein the antioxidant employed in step (d~~2~~) is butylated hydroxy toluene or alpha-tocopherol.

33. (**Currently Amended**) The process in accordance with claim 26, wherein the emulsion-stabilizing agent employed in step (d~~2~~) is polyethylene glycol 400 (PEG 400).

34. (**Currently amended**) The process in accordance with claim 26, wherein the polarity corrector employed in step (d) is citric acid or ascorbic acid.

35. (**Currently amended**) The process in accordance with claim 26, wherein the surfactant employed in step (f) is polyethoxylated castor oil 35, polyethoxylated hydrogenated castor oil 40, ~~and/or~~ polysorbate~~s~~ 20, polysorbate 40, polysorbate 60, ~~or~~ polysorbate 80 or a mixture of at least two thereof.

36. (**Canceled**)

37. (**New**) A stable and soluble pharmaceutical composition prepared by the process of claim 26 comprising:

ritonavir in an amount ranging from 10% to 50% w/w of the final composition;

a mixture of alcoholic solvent and alcoholic co-solvent of C_2-C_4 in a total amount ranging from 10% to 30% w/w of the final composition;

a mixture of C_8-C_{10} medium chain mono/diglycerides in an amount ranging from 20% to 40% w/w of the final composition;

a pharmaceutically suitable surfactant in an amount ranging from 0.1% to 20% w/w of the final composition;

an antioxidant in an amount ranging from 0.001% to 2.0% w/w of the final composition.

38. (**New**) The pharmaceutical composition in accordance with claim 37, which further comprises:

an emulsion -stabilizing agent in an amount ranging up to 60% w/w of the final composition;

a polarity corrector agent in an amount up to 0.5% of the final composition.

39. (**New**) The pharmaceutical composition in accordance with claim 37, comprising the alcoholic solvent in an amount ranging from 5.0% to 15% w/w of the final composition.

40. (**New**) The pharmaceutical composition in accordance with claim 37, comprising the alcoholic co-solvent in an amount ranging from 5.0% to 15% w/w of the final composition.

41. (**New**) The pharmaceutical composition in accordance with claim 37, wherein the alcoholic solvent is ethanol and the alcoholic co-solvent is propylene glycol.

42. (**New**) The pharmaceutical composition in accordance with claim 37, wherein the surfactant is polyethoxylated castor oil 35, polyethoxylated hydrogenated castor oil 40, polysorbate 20, polysorbate 40, polysorbate 60, polysorbate 80 or a mixture of at least two thereof.

43. (**New**) The pharmaceutical composition in accordance with claim 37, wherein the antioxidant is butylated hydroxy toluene or alpha-tocopherol.

44. (**New**) The pharmaceutical composition in accordance with claim 37, wherein the emulsion-stabilizing agent is polyethylene glycol 400 (PEG 400).

45. (**New**) The pharmaceutical composition in accordance with claim 38, wherein the polarity corrector agent is citric acid or ascorbic acid.